New data from APTneo Michelangelo trial presented during San Antonio Breast Cancer Symposium
Higher pathologic complete response rate with atezolizumab added to anthracycline and cyclophosphamide and chemotherapy plus trastuzumab/pertuzumab in HER2+ breast cancer